Evonik's Potential Windfall: Navigating US Tariff Repercussions
Published on 02/28/2026 at 04:23 | Redaktion boerse-global.de
The German specialty chemicals group Evonik is evaluating a strategic move in the ongoing US tariff dispute that could yield a notable financial benefit: the potential recovery of duties already paid. While this may seem like a procedural detail, the sums involved quickly reach a significant scale. This analysis explores the company's financial and strategic positioning regarding this issue.
A Tactical Financial Opportunity
During a recent podcast, interim CFO Claus Rettig indicated that Evonik could potentially reclaim an amount in the "lower double-digit millions" of euros. The company's approach, however, is deliberately measured. Concrete steps toward reclaiming these funds will only be initiated once the future course of action by the US administration becomes clearer. This stance allows Evonik to maintain both legal and financial flexibility while it monitors developments.
A key mitigating factor for the company is its limited direct exposure to these tariffs. A substantial portion of the products destined for the American market is manufactured locally within the United States. This localized production footprint cushions the immediate financial impact of the tariffs and explains why Evonik views the situation more as a tactical challenge than an existential threat.
A Dual-Edged Sword for Competition
According to Rettig, the current trade policy landscape presents a mixed picture. Although tariffs inherently increase costs, they can simultaneously confer an advantage to suppliers with established US production. Evonik identifies a potential positive effect precisely here: competition from Chinese rivals in the US market has weakened due to the tariff regime. This dynamic could bolster Evonik's own position in the region, even as the broader tariff dispute continues to create market uncertainty.
Despite this complex environment, the corporation reaffirms its foundational principles. Evonik remains committed to open markets, free global trade, and fair competition.
Should investors sell immediately? Or is it worth buying Evonik?
Market Performance: Short-Term Pressure vs. Medium-Term Recovery
Sentiment on the stock market remains mixed. Evonik shares closed at €14.73 on Friday, marking a daily decline of 1.60%. While the stock shows a 30-day gain of 13.57%, its performance over a twelve-month period remains deeply negative, down 23.14%.
A notable technical indicator is the 14-day Relative Strength Index (RSI), which stands at a very low 15.8. This level typically signals strongly oversold conditions. Concurrently, the share price is trading just below its 200-day moving average of €15.27, underscoring the persistent downward pressure visible on the chart.
In summary, the tariff issue represents a financial lever for Evonik, albeit one with a currently limited scope. The situation will only become concrete once the company formally files any reclaims and the next round of US policy decisions is finalized.
Ad
Evonik Stock: New Analysis - 28 February
Fresh Evonik information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
